Retatrutide, a groundbreaking dual-acting glucose-regulated incretin analog, represents a significant progression in peptide therapeutics for the management of type 2 diabetic conditions and, increasingly, weight issues. Unlike many existing medicinal interventions, retatrutide integrates the actions of a GLP-1 receptor activator and a GIP receptor